Novel chemotherapy-free strategy shows promise in patients with HER2-positive and hormone-receptor positive metastatic breast cancer (HER2+/HR+)

Novel chemotherapy-free strategy shows promise in patients with HER2-positive and hormone-receptor positive metastatic breast cancer (HER2+/HR+)

Results from an international Phase IIa study point to the promise of adding bispecific HER2-targeted antibody zanidatamab to the combination…

VHIO discovers potential use of breast milk liquid biopsy for the early diagnosis of breast cancer

Researchers at the Vall d’Hebron Institute of Oncology (VHIO), part of the Vall d’Hebron Campus, have found that breast milk…

Novel AKT inhibitor combined with standard hormone therapy shows promise for patients with pre-treated metastatic HR+/ HER2- breast cancer

Approximately 70% of advanced breast cancers are hormone receptor-positive (HR+)/HER2-negative. Hormone therapies are widely used for the treatment of patients…

SOLTI-TOT-HER3 window of opportunity trial: final results show that lower dose patritumab deruxtecan is less toxic and does not compromise efficacy in the treatment of breast cancer

Presented at the 2023 ESMO Breast Cancer Annual Congress, 11-13 May in Berlin, final results of the SOLTI-TOT-HER3 window of…

POSITIVE results show that temporarily discontinuing endocrine therapy to attempt pregnancy after breast cancer does not increase the short-term risk of disease relapse

Published in The New England Journal of Medicine (1), first results of the international POSITIVE study co-authored by VHIO’s Cristina…

1 2

Breast Cancer Group